SIRO
Sirona Dental Systems, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Mon, Feb. 29, 11:32 AM
    • The previously announced merger between Dentsply (XRAY +0.6%) and Sirona Dental Systems (SIRO) has been completed. Under the terms of the all-stock transaction, Sirona shareholders received 1.8142 shares of XRAY for each Sirona share. SIRO will cease trading today.
    • The combined company will do business as DENTSPLY SIRONA and will trade under the symbol "XRAY."
    • Previously: Dentsply and Sirona to merge (Sept. 15, 2015)
    | Mon, Feb. 29, 11:32 AM
  • Fri, Feb. 26, 3:10 AM
    • PrivateBancorp (NASDAQ:PVTB) will replace Sirona Dental Systems (NASDAQ:SIRO) in the S&P MidCap 400.
    • Cogent Communications (NASDAQ:CCOI) will replace PrivateBancorp in the S&P SmallCap 600
    • Both will occur after the close of trading on Monday, February 29.4
    • Dentsply (NASDAQ:XRAY) is acquiring Sirona in a deal expected to be completed on or about that date. Dentsply (soon to be Dentsply Sirona) is an S&P 500 component.
    | Fri, Feb. 26, 3:10 AM
  • Mon, Feb. 8, 6:45 AM
    • Sirona Dental Systems (SIRO) FQ1 results: Revenues: $304.2M (+3.8%); R&D Expense: $13.3M (-10.1%); SG&A: $96.4M (+9.8%); Operating Income: $66.7M (+6.2%); Net Income: $51.3M (+11.5%); EPS: $0.91 (+11.0%); Non-GAAP EPS: $0.99 (+3.1%); Quick Assets: $485M (-6.3%).
    • No guidance given.
    | Mon, Feb. 8, 6:45 AM
  • Mon, Feb. 8, 6:06 AM
    • Sirona Dental Systems (NASDAQ:SIRO): FQ1 EPS of $0.99 beats by $0.01.
    • Revenue of $304.2M (+3.8% Y/Y) beats by $3.77M.
    | Mon, Feb. 8, 6:06 AM
  • Nov. 20, 2015, 6:43 AM
    • Sirona Dental Systems (SIRO +0.9%) FQ4 results: Revenues: $304.9M (+5.1%); R&D Expense: $12.9M (-21.8%); SG&A: $90.2M (+3.0%); Operating Income: $65.1M (+11.7%); Net Income: $45.4M (+6.3%); EPS: $0.80 (+5.3%); Non-GAAP EPS: $1.12 (+20.4%).
    • FY2015 results: Revenues: $1,161.3M (-0.8%); R&D Expense: $54.8M (-15.2%); SG&A: $344.1M (-1.9%); Operating Income: $258.3M (+8.5%); Net Income: $186.2M (+6.0%); EPS: $3.30 (+5.4%); Non-GAAP EPS: $3.98 (+8.4%); Quick Assets: $517.8M (+35.3%).
    • No guidance given.
    | Nov. 20, 2015, 6:43 AM
  • Nov. 20, 2015, 6:32 AM
    • Sirona Dental Systems (NASDAQ:SIRO): FQ4 EPS of $1.12
    • Revenue of $304.9M (+5.1% Y/Y) beats by $9.93M.
    | Nov. 20, 2015, 6:32 AM
  • Nov. 19, 2015, 5:30 PM
    | Nov. 19, 2015, 5:30 PM | 3 Comments
  • Sep. 18, 2015, 10:11 AM
    • Anthera Pharmaceuticals (ANTH +3.3%) initiated with Buy rating and $15 (56% upside) price target by Citi.
    • Trovagene (TROV +4.2%) initiated with Buy rating and $10 (47% upside) price target by Cantor Fitzgerald.
    • Bruker (BRKR -1.1%) initiated with Equal Weight rating and $21 (16% upside) price target by Morgan Stanley.
    • Align Technology (ALGN -0.8%) initiated with Outperform rating and $70 (21% upside) price target by Leerink.
    • WebMD (WBMD -0.8%) upgraded to Outperform from Market Perform by Cowen & Co. Price target raised to $53 (29% upside) from $42.
    • Dentsply (XRAY -0.7%) upgraded to Outperform from Market Perform by Baird. Price target raised to $61 (15% upside) from $58.
    • Dentsply (XRAY -0.7%) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $70 (32% upside) from $56.
    • Vertex Pharmaceuticals (VRTX -4.2%) upgraded to Overweight from Equal Weight by Barclays. Price target raised to $150 (16% upside) from $120.
    • Sirona Dental Systems (SIRO -0.8%) downgraded to Equal Weight by Morgan Stanley.
    • Amicus Therapeutics (FOLD -0.1%) downgraded to Neutral from Buy by Chardan Capital Markets. Price target is $17.50 (0% upside).
    • Raptor Pharmaceuticals (RPTP -0.7%) downgraded to Neutral from Buy by Citi. Price target lowered to $8 (16% upside) from $20.
    • Alexion Pharmaceuticals (ALXN -0.7%) downgraded to Equal Weight from Overweight by Barclays. Price target lowered to $205 (23% upside) from $220.
    | Sep. 18, 2015, 10:11 AM | 5 Comments
  • Sep. 15, 2015, 4:32 PM
    • Dentsply (NASDAQ:XRAY) and Sirona Dental Systems (NASDAQ:SIRO) will combine in an all-stock merger of equals.  The marriage will create the world's largest manufacturer of professional dental products and technologies with a pro forma equity value of $13.3B.
    • Net revenue of the combined firms is ~$3.8B with  adjusted EBITDA of ~$900M (trailing 12 mo.).
    • Update: In premarket trading, XRAY and SIRO are both down 4% on higher-than-normal volume.
    | Sep. 15, 2015, 4:32 PM
  • Aug. 7, 2015, 9:38 AM
    • Sirona Dental Systems (SIRO +0.9%) FQ3 results: Revenues: $306.1M (+2.1%); COGS: $131.5M (-0.5%); R&D Expense: $12.9M (-22.3%); SG&A: $84M (-4.7%); Operating Income: $80.4M (+19.5%); Net Income: $58.8M (+14.2%); EPS: $1.04 (+13.0%); Quick Assets: $422.6M (+10.4%).
    • FY15 Guidance: Organic local currency revenue growth: 6% - 8%; non-GAAP adjusted EPS: $3.95 - 4.05.
    | Aug. 7, 2015, 9:38 AM
  • Aug. 7, 2015, 6:31 AM
    • Sirona Dental Systems (NASDAQ:SIRO): FQ3 EPS of $1.16 beats by $0.01.
    • Revenue of $306.1M (+2.1% Y/Y) beats by $10.26M.
    | Aug. 7, 2015, 6:31 AM
  • Aug. 6, 2015, 5:30 PM
    | Aug. 6, 2015, 5:30 PM | 5 Comments
  • May 8, 2015, 6:31 AM
    • Sirona Dental Systems (NASDAQ:SIRO): FQ2 EPS of $0.76 beats by $0.01.
    • Revenue of $257.3M (-9.0% Y/Y) misses by $6.46M.
    | May 8, 2015, 6:31 AM
  • May 7, 2015, 5:30 PM
    | May 7, 2015, 5:30 PM | 7 Comments
  • Feb. 6, 2015, 6:49 AM
    • Sirona Dental Systems (SIRO +1.7%) FQ1 results: Revenues: $293M (-1.9%); COGS: $130.1M (-4.3%); R&D Expense: $14.8M (-2.0%); SG&A: $87.8M (-0.2%); Operating Income: $62.8M (+1.1%); Net Income: $46M (+4.1%); EPS: $0.82 (+3.8%); Quick Assets: $368.1M (-3.8%); CF Ops: $4.2m (-62.8%).
    • Fiscal 2015 Guidance: Revenue Growth: 6 - 8%; non-GAAP Adjusted EPS: $3.95 - 4.05; GAAP EPS: $3.45 - 3.57.
    | Feb. 6, 2015, 6:49 AM
  • Feb. 6, 2015, 6:32 AM
    • Sirona Dental Systems (NASDAQ:SIRO): FQ1 EPS of $0.96 beats by $0.02.
    • Revenue of $293M (-1.9% Y/Y) beats by $1.56M.
    | Feb. 6, 2015, 6:32 AM